Clinical trials: Prostate Ca immunotherapy well toleratedJune 24th 2010
Sipuleucel-T (Provenge), an autologous cellular immunotherapy for metastatic, hormone-resistant prostate cancer, demonstrated few adverse events compared with controls in analysis of randomized clinical trials presented at the AUA annual meeting in San Francisco.
Injectable prostate Ca agent shows continued benefits beyond 1 yearJune 10th 2010
Prostate cancer patients on leuprolide (Lupron Depot) who were offered to continue on degarelix (Firmagon) after 1 year of treatment reduced PSA recurrence, according to results of a phase III extension study presented at the AUA annual meeting in San Francisco.
FDA: GnRH agonists associated with small risk of diabetes, deathMay 13th 2010
Gonadotropin-releasing hormone (GnRH) agonists have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several FDA studies.
Prostate cancer prevention: Men can lower risk 25% with 5-ARIsMay 1st 2010
Selenium and vitamin are E not promising, but both the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial showed a 20% to 25% reduction in the incidence of prostate cancer from two different 5-alpha-reductase inhibitors, finasteride (Proscar) and dutasteride (Avodart).
Botulinum toxin offers minimally invasive Tx for idiopathic OABApril 29th 2010
Botulinum toxin A (Botox, Dysport) appears to be beneficial for the treatment of patients with idiopathic overactive bladder that is not adequately managed by anticholinergic drug therapy, according to a double-blind, placebo-controlled study presented at the European Association of Urology annual congress in Barcelona, Spain.
RCC treatment-related hypertension may be marker for efficacyApril 15th 2010
A retrospective, exploratory analysis of prospective clinical trials showed treatment-related hypertension was associated with significantly greater progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with sunitinib (Sutent), researchers reported at the 2010 Genitourinary Cancers Symposium in San Francisco.
Dutasteride data show reduction in PCa risk; editorial disputes clinical relevanceApril 15th 2010
Recently published study results indicate that dutasteride (Avodart) reduces the risk of prostate cancer in high-risk men, but publication of the results and an accompanying editorial may reignite the debate over whether 5-alpha-reductase inhibitors promote the growth of high-grade tumors.
This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes phase II, III, and IV erectile dysfunction trials that are currently recruiting participants. This list is current as of March 17, 2010.
Phase III results confirm survival improvement with PCa immunotherapyMarch 25th 2010
Sipuleucel-T (Provenge) extends overall survival in men with metastatic, castrate-resistant prostate cancer, investigators in Dendreon Corp.?s phase III IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study recently announced at the 2010 Genitourinary Cancers Symposium in San Francisco.
Advanced PCa treatment increases progression-free survival in phase III studyMarch 25th 2010
Results from a phase III trial have shown that cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel (Taxotere)-based chemotherapy.
Comparison study: Denosumab is better at delaying skeletal events in PCaFebruary 25th 2010
Denosumab appears to delay skeletal-related events in patients suffering from metastatic prostate cancer, according to results of a phase III, head-to-head trial evaluating denosumab versus zoledronic acid (Zometa).
On-demand aerosol spray increases ejaculatory latencyJanuary 28th 2010
An investigational treatment for premature ejaculation, PSD502, appears to delay ejaculation up to five times longer than placebo, according to a study presented at the 2009 Sexual Medicine Society of North America annual meeting in San Diego.
Botulinum toxin shows efficacy in detrusor overactivityJanuary 1st 2010
A recent study designed to determine the efficacy of intravesical botulinum toxin in patients with neurogenic detrusor overactivity and urinary incontinence secondary to spinal cord injury or multiple sclerosis showed positive results.